TRIFILL Pro
CO2 subcision plus drug delivery platform (limited direct evidence)
이 치료에 대해
TRIFILL Pro is a Korean platform combining CO2-based subcision and drug delivery. It is not a drug itself, but a procedural system integrating a device with injection techniques.
As of April 2026, peer-reviewed evidence specific to TRIFILL Pro is limited. High-quality comparative trials for acne scars remain scarce, so indication decisions should be cautious.
작용 기전
A typical sequence is CO2-assisted release of tethering, followed by drug delivery and redistribution to improve scar release and distribution uniformity. Improved perfusion and fibroblast stimulation are hypothesized, but mechanism-specific proof for TRIFILL Pro is still limited.
적응증
기대 효과
Public information is mainly manufacturer materials and case-based real-world reports, while high-quality TriFill Pro-specific comparative trials (RCTs) remain limited as of April 2026.
임상 근거
위험 및 부작용
Pain, erythema, swelling, crepitus-like sensation, and bruising may occur. Injection-related complications (infection, intravascular events) must be considered. Because public IFU-level information is limited, robust informed consent is essential for off-label use.